Global pharma major Lupin Limited (Lupin) announced the launch of rufinamide oral suspension, 40 mg/mL to market a generic equivalent of Banzel oral suspension, 40 mg/mL of Eisai Inc.
Rufinamide oral suspension had estimated annual sales of USD 72 million in the US (IQVIA MAT April 2023).
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the US, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
